Key Highlights
- AVITA Medical (RCEL) has beaten the market by 181.4 percentage points over six months and is up 233.7% year-to-date.
- The broader session move was +5.8% versus a +2.3% peer median, a company-specific gain tied to completion of the PermeaDerm trial.
- Short interest is 9% of shares outstanding with 10.5 days to cover as of Sept. 15.
AVITA Medical (NASDAQ:RCEL) rose 0.5% to $11.64 after completing its PermeaDerm trial, leaving the wound-care stock just below its 52-week high and up 233.7% this year. It has outperformed the market by 181.4 percentage points over six months, helped by raised 2026 guidance and a new CEO, while 9% of shares are sold short with 10.5 days to cover.
AVITA Medical has outperformed the broader market by 181.4 percentage points over the past six months. AVITA makes the RECELL system, which uses a patient's own skin cells to treat burns, skin defects and vitiligo, and PermeaDerm, a wound dressing that a study showed can cost about 70% less than donor skin grafts.
The run started with the Aug. 7 report, when Q2 Revenue rose 18% to $21.7 million and the company raised its 2026 revenue guidance, sending the stock up 63.6% in one day. It added another 24.7% on Aug. 18. New CEO Cary Vance took over about four months ago, and the company presented at a Morgan Stanley healthcare conference this month.
AVITA Medical (RCEL) Outruns Peers
Cabaletta Bio rose 2.7% and Zentalis gained 1.8%, but RCEL's move was driven by its own news. The $0.63 move equaled about 1.0x the 14-day average true range of $0.66, and about $4.87 million traded versus a typical $4.09 million. RCEL closed mid-range between $10.90 and $11.76. The 52-week range is $3.22 to $11.81, and the market Capitalization is about $358 million.
RCEL Technical Levels: Strong Trend, Near Resistance
RCEL trades above its 20-day Moving Average of $10.60, its 50-day of $8.29 and its 200-day of $5.21, a clean uptrend on every time frame.
The 14-day RSI is 66.2. RSI measures recent gains versus losses on a 0 to 100 scale, and a reading in the mid-60s shows strong momentum just below the 70 overbought line.
MACD is 0.75, slightly below its 0.81 signal line. MACD tracks momentum, and dipping below the signal line hints the pace of gains is slowing.
ADX is 47.1. ADX measures trend strength, and a reading near 50 shows a very strong trend.
First resistance is $12.47, then $14.83. Support is much lower at $6.04, so a breakout above $12.47 is the next test. With 10.5 days to cover, a break higher could pressure short sellers.
Growth Company Still Losing Money
Trailing-twelve-month revenue is $75.63 million, with an 81.6% gross Margin but a -46.6% Operating Margin and -57.0% net margin. AVITA holds $9.14 million of cash and equivalents, has 30.9 million shares outstanding and 226 employees, and trades at 4.5 times sales. Analysts rate the stock a Strong Buy with an average target of about $12.31 to $12.46, close to the current price.
Peers Moving on This News
- Cabaletta Bio (NASDAQ:CABA) up 2.7%
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) up 1.8%

_11_20_2026_19_30_07_879097.jpg)

_11_20_2026_19_32_49_884922.jpg)


Please wait processing your request...